Parenteral Manual

Ampicillin sodium

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
PENBRITIN®, AMPICIN®
Classification: 
Antibiotic
Original Date: 
August 2005
Revised Date: 
October 2018
Indications: 
  • Semisynthetic penicillin for the treatment of infections due to susceptible bacteria
  • Endocarditis prophylaxis
Reconstitution and Stability: 

 

VIAL SIZE STERILE WATER FOR INJECTION REQUIRED FINAL CONCENTRATION
500 mg 4 mL 125 mg/mL
1000 mg 7.4 mL 125 mg/mL
  • Powder is stable at room temperature   
  • Reconstituted solution stable 1 hour at room temperature or 4 hours refrigerated                 
  • Solutions diluted in D5W stable for 1 hour only
Compatibility: 
  • Solutions Compatible: 0.9% NaCl, ringer's solution, D5W (but only for 1 hour)
  • Additives/Above Cassette Compatible : no information
  • Y-site Compatible:  potassium chloride (up to 40 mmol/L), morphine

Incompatible: TPN, Do not mix with aminoglycosides. Flush line well between administration of beta-lactams and aminoglycosides

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM YES, deeply into large muscle
Usual dilution: <250 mg/mL
IV Direct

Yes, into large vessel

Usual dilution: 125 mg/mL

Infusion rate:

Patient less than or equal to 10 kg: do not exceed 10 mg/kg/minute

Patient greater than 10 kg: Do not exceed 100 mg/minute

IV Intermittent Infusion

Yes

Usual dilution: 125 mg/mL

Infusion time: 15-30 minutes

 

Infusion rate:

Patient less than or equal to 10 kg: do not exceed 10 mg/kg/minute

Patient greater than 10 kg: Do not exceed 100 mg/minute

IV Continuous Infusion NO
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Pediatric:

  • Usual: 100-200 mg/kg/day ÷ Q 6 hours (Maximum : 12 g/day)
  • Meningitis: 300-400 mg/kg/day ÷ Q 4 hours (Maximum : 12 g/day)
  • Q4H recommeded for bacteremia, endocarditis, meningitis and osteromyelitis
  • Endocarditis prophylaxis: 50 mg/kg/dose (max 2 g) given 1 hour  before procedure

Adolescent/Adult:  

  • Usual adult dose 0.5  to 3 g Q 6 hours (Maximum : 14 g/day)
  • Endocarditis prophylaxis:  2 g given 1 hour before procedure

DOSAGE ADJUSTMENT IN RENAL IMPAIRMENT:

CrCl 10-30 mL/min: administer Q 6-12 hours CrCl < 10 mL/min: administer Q 12 hours

Potential hazards of parenteral administration: 
  • Hypersensitivity reactions - immediate and delayed 
  • Too rapid IV can produce convulsions or muscular irritability;  maximum rate 10 mg/kg/min to a max of 100 mg/minute
  • Possibility of severe pain at injection site  
  • Rash, pruritis, urticaria, nausea, vomiting, diarrhea                                            
Notes: 
  • With prolonged therapy, monitor renal, hepatic and hematologic function periodically
  • Hyperuricemia or allopurinol may potentiate ampicillin rash
  • Caution in patients allergic to penicillin or cephalosporins (may be cross-sensitive)
  • Contains 3.1 mmol sodium/g of ampicillin
  • False positive urinary glucose for Clinitest, Fehling, and Benedicts solution

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.